Biomarkers and Personalized Approach to Cancer Group (BioPAC)
Group leader
Bruno Sainz Anding
Tlf.: + 34 91 497 54 20
Principal Investigator
- María Isabel Sánchez Pérez
- Julie Earl
- Alfredo Carrato Mena
- María Ángeles Vaz Salgado
Collaborating Staff
- Sonia Alcalá Sánchez
- Laura Martín Hijano
- Diego Navarro Vera
- Laura Ruiz Cañas
- Adrian Palencia Campos
- Juan Carlos Lopez Gil
- Jorge Melones Herrero
- Emma Barreto Melian
- María Reyes Ferreiro Monteagudo
- Federico Longo Muñoz
- Mercedes Rodríguez Garrote
- Ainara Soria Rivas
- Jorge Juan Villalon Lopez

Principal Investigator
- María Isabel Sánchez Pérez
- Julie Earl
- Alfredo Carrato Mena
- María Ángeles Vaz Salgado
Collaborating Staff
- Sonia Alcalá Sánchez
- Laura Martín Hijano
- Diego Navarro Vera
- Laura Ruiz Cañas
- Adrian Palencia Campos
- Juan Carlos Lopez Gil
- Jorge Melones Herrero
- Emma Barreto Melian
- María Reyes Ferreiro Monteagudo
- Federico Longo Muñoz
- Mercedes Rodríguez Garrote
- Ainara Soria Rivas
- Jorge Juan Villalon Lopez
Strategic objectives
- Actively participate in national and international networks and projects in the cancer field, with a focus on the biology of cancer stem cells and the tumour microenvironment.
- Develop new technologies and systems for personalised medicine focused on the identification of drugs that eliminate cancer stem cells.
- Reinforce alliances and collaborations between the business, academic and public health sectors.
- Drive scientific and technological excellence at European level by constituting a fundamental frame of reference in cancer-based studies.
Research lines
- Identification and characterisation of new biomarkers for the detection of CSCs in different solid tumours.
- Identification of key proteins to develop and/or maintain the phenotype of CSCs, which includes characteristics such as pluripotency, epithelium-mesenchymal transition (EMT), oxidative phosphorylation or chemoresistance.
- Characterisation of the cell niche and the tumour microenvironment that surrounds the CSCs and the communication between both.
- Development of the liquid biopsy for the isolation of blood cancer stem cells for their characterisation and validation as an early cancer detection marker.
- Development of a platform to evaluate the chemosensitivity of cancer stem cells to drugs for application in personalised medicine.
Location
Faculty of Medicine
Laboratory B33/B35
Madrid Autonomous University
+34 91 497 54 20
Keywords
cancer stem cells, tumour microenvironment, tumour associated macrophages, ductal pancreatic adenocarcinoma, chemoresistance, mitochondrial respiration, oncolytic viruses